<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tacrolimus is widely used for the prophylaxis and treatment of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> after allogeneic hematopoietic stem cell transplantation (HSCT) and graft rejection in solid organ transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The metabolism of tacrolimus has been reported to be impaired in association with <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo>, mostly as documented in liver transplant recipients </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">Hepatic veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) is one of the serious complications after allogeneic HSCT </plain></SENT>
<SENT sid="3" pm="."><plain>It is characterized by <z:hpo ids='HP_0000952'>jaundice</z:hpo>, fluid retention, and painful <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo>, caused by endothelial cell injury resulting from the toxicity of the conditioning regimen </plain></SENT>
<SENT sid="4" pm="."><plain>The impaired metabolism of tacrolimus in hepatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> has not previously been reported in the literature </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we report the notable alteration in the metabolism of tacrolimus in two patients with hepatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>, in whom the half-lives of tacrolimus were markedly prolonged (288 and 146 h) </plain></SENT>
</text></document>